Nanogen Shares Down 6.7 Percent on Lackluster Q4 Revenues, Widened Losses | GenomeWeb

Nanogen Shares Down 6.7 Percent on Lackluster Q4 Revenues, Widened Losses

Feb 24, 2005

NEW YORK, Feb. 24 (GenomeWeb News) - Shares in Nanogen were down 6.67 percent, or $.29, at $4.07 in late-afternoon trading after the company yesterday reported a 51-percent fall-off in fourth-quarter revenue and an 89-percent increase in its net losses.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Breaking News

The Scan

The Apple's Journey

The apple has traveled westward and eastward along the Silk Road, according to a new genetic analysis.

This Week in Nature

In Nature this week: GWAS data used to reposition drugs for psychiatric use, and more.

Change Is Hard to Do

Genetic disease risk information doesn't always spur people to make healthy lifestyle changes, according to the Associated Press.

Possible Paths for CUP

A University of California, San Diego-led team has used liquid biopsies to uncover possible treatments for patients with cancers of unknown primary.